2023
The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
Feikin D, Karron R, Saha S, Sparrow E, Srikantiah P, Weinberger D, Zar H. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases 2023, 24: e318-e327. PMID: 38000374, DOI: 10.1016/s1473-3099(23)00568-6.Peer-Reviewed Original ResearchLower respiratory tract infectionsRespiratory syncytial virusRSV diseaseRespiratory illnessSyncytial virusRespiratory diseaseAcute lower respiratory tract infectionPrevention of RSVAcute respiratory illnessRespiratory tract infectionsImportant public health benefitsInappropriate antibiotic useSevere respiratory illnessCause infant mortalityCost-effective interventionPublic health benefitsHealth care systemMaternal vaccinesRecurrent hospitalisationsRSV preventionSecondary pneumoniaTract infectionsMiddle-income countriesLung healthAntibiotic use
2011
Serotype replacement in disease after pneumococcal vaccination
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. The Lancet 2011, 378: 1962-1973. PMID: 21492929, PMCID: PMC3256741, DOI: 10.1016/s0140-6736(10)62225-8.Peer-Reviewed Original ResearchConceptsNon-vaccine serotypesSerotype replacementPneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePneumococcal conjugate vaccineImportant public health benefitsBenefits of vaccinationPublic health benefitsDisease surveillance systemsNVT carriagePneumococcal vaccinationSurveillance biasesConjugate vaccineVaccine serotypesCarriage prevalencePneumococcal serotypesAsymptomatic carriersCarriage dataDiseaseVaccinationHealth benefitsLow invasivenessPrevalenceSerotypesCarriage